Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management
VANCOUVER, BC , Aug. 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development...
/CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, released its second...
Filament's botanical psilocybin drug candidate PEX010 to be administered in Germany for treatment-resistant depression
/CNW/ - Filament Health Corp. (OTC:FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the...
/CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that...
UCL will study PEX010, the company's botanical psilocybin drug candidate, in trials investigating human perception, cognition, and therapeutic optimization
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications
/CNW/ - Filament Health Corp. (OTC:FLHLF) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that...
/CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical–stage natural psychedelic drug development company, today announced that...